Lokoid ointment appearance. 0.1% 30g tuba

Description

Composition
Active substance:
1 g of ointment contains: hydrocortisone 17- butyrate -1 mg ,.
Excipients:
Polyethylene ointment base (vaseline oil 95% polyethylene 5%) – q.s. and 1.0 g
Description:
Translucent, from light gray to almost white uniform soft, fatty ointment.
Product form:
Ointment for external use 0.1%.
30 g of the ointment was placed in an aluminum tube with an aluminum membrane and the screw cap of high density polyethylene. 1 tube together with instructions for use in a cardboard package.
Contraindications
Hypersensitivity to hydrocortisone or auxiliary ingredients. bacterial skin infection (stafilodermii and streptococci, gram negative folliculitis, etc.); viral skin infections (herpes simplex, chicken pox, shingles, etc.) fungal infections of the skin; tubercular and syphilitic lesions of the skin; parasitic infections of the skin; neoplastic skin lesions (benign and malignant tumors); acne, rosacea, perioral dermatitis; post-vaccination period; violation of integrity of the skin (wounds, ulcers);
Precautions: Pregnancy, lactation.
Dosage
0.1%
Indications
Surface, uninfected, glucocorticosteroids sensitive to local skin diseases: dermatitis, including atopic, contact, seborrheic; eczema; psoriasis.
Can be used in children from 6 months of age. In the case of the drug in children in the area of ​​the face or under occlusive dressings duration of the course of treatment should be reduced.
When used in children skin surface area on which drug is applied should not exceed 20% of the total.
In childhood, the suppression of adrenocortical function may develop more quickly. Furthermore, there may be a decrease of excretion of growth hormone. In applying the drug for a long time is required to observe the body weight, height, level of plasma cortisol. In a study in children receiving 30-60 g lokoid a week for 4 weeks, compared with 1% hydrocortisone ointment, none of the children were not detected violations of adrenocortical function, the differences hydrocortisone 17-butyrate on the indicator from conventional hydrocortisone was not observed.
Interaction with other drugs
data on drug interactions lokoid not.
Overdose
Data on overdose lokoid not. Prolonged use of high doses of the drug may increase the above-described side effects. When the symptoms of Cushing’s medication should be discontinued.
pharmachologic effect
Pharmacological group:
Glucocorticosteroids for local use.
Pharmacological properties:
Lokoid® is a synthetic non-halogenated glucocorticosteroid for external application. Esterification molecule hydrocortisone residue butyric acid (butyrate) afforded radically improve drug activity as compared to native hydrocortisone. Lokoid® has rapidly occurring anti-inflammatory, anti, antipruritic effect.
Application lokoid at recommended doses does not cause suppression of the hypothalamic-pituitary-adrenal system. Although the use of high doses for long periods, especially when using occlusive dressings may lead to an increase in cortisol in the blood plasma, it is not usually accompanied by a decrease in reactivity of the pituitary-adrenal system, and removal of the drug results in a rapid normalization of cortisol production.
Pharmacokinetics:
Suction
After application of the active substance accumulation in the epidermis, mainly in the granular layer, systemic absorption is negligible. A small amount of hydrocortisone 17-butyrate is absorbed into the systemic circulation in an unchanged form.
Metabolism
Most of hydrocortisone 17-butyrate, hydrocortisone and metabolized to other metabolites directly in the epidermis and subsequently in the liver.
breeding
Metabolites and a small portion of unchanged hydrocortisone 17-butyrate is excreted by the kidneys and through the intestines.
Pregnancy and breast-feeding
Glucocorticosteroids cross the placenta. Effects on the fetus can be especially pronounced when applying the drug to large surfaces. No data on the number of hydrocortisone, is excreted in breast milk; It recommended to be very careful when administering the drug during lactation.
Conditions of supply of pharmacies
Without a prescription.
side effects
Local reactions: skin irritation, on rare occasions – other local reactions characteristic of the outer steroid therapy.
Systemic reactions:
With prolonged use, applied to large surfaces and / or the use of occlusion may experience side effects characteristic of systemic corticosteroids. The risk of local and systemic side effects when applied lokoid lower than when using a fluorinated steroid.
special instructions
Do not apply Lokoid in the periorbital region due to the risk of developing glaucoma. At regular contact with the conjunctiva there is a risk of increasing intraocular pressure.
Any steroids for external application in the form of ointments not desirable to use on the scalp, as well as acute inflammation (particularly exudative). For the treatment of steroid-responsive skin lesions localized in the face, folds, genitals and skin sections with abundant scalp preferable to use other lokoid dosage forms (cream, Krel).
The drug is not desirable to use in the presence of atrophic skin changes.
The risk of local and systemic side effects increases when applied to large swathes of destruction, long-term use, and the use of occlusion in childhood.
If no effect within 2 weeks of continuous treatment, it is necessary to clarify the diagnosis.
As with any glucocorticosteroid drug, it is desirable to limit the duration of application and driving the minimum dose sufficient for the relief of skin process.
Data on the impact of lokoid on ability to drive and work with no mechanisms.
Storage conditions
At a temperature of not higher than 25 C.
In the reach of children.
Dosing and Administration
Outwardly.
Lokoid in the form of an ointment used for subacute and chronic processes, especially in the presence lichenification, permeation dryness.
The drug is applied to the affected skin a thin layer of 1-3 times a day. When the positive dynamics in the multiplicity of the drug can be reduced to 2-3 times a week. To improve the penetration of drug applied massaging movements. In the case of resistance the disease, such as the localization of dense psoriasis plaques on ulnar areas, knees, the drug can be used under occlusive dressings. The dose of the drug used during the week should not exceed 30-60 g
Information
Appearance may differ from that depicted in the picture. There are contraindications. You need to read the manual or consult with a specialist